Rezolute, Inc. (RZLT)
NASDAQ: RZLT · Real-Time Price · USD
4.260
+0.260 (6.50%)
Jun 3, 2026, 12:17 PM EDT - Market open
Rezolute Employees
Rezolute had 68 employees as of March 31, 2026. The number of employees did not change compared to the same quarter last year.
Employees
68
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,198,309
Market Cap
445.03M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 68 | 0 | - |
| Dec 31, 2025 | 75 | 11 | 17.19% |
| Sep 30, 2025 | 75 | 57 | 316.67% |
| Jun 30, 2025 | 71 | 12 | 20.34% |
| Mar 31, 2025 | 68 | 13 | 23.64% |
| Dec 31, 2024 | 64 | 7 | 12.28% |
| Sep 30, 2024 | 18 | -32 | -64.00% |
| Jun 30, 2024 | 59 | 8 | 15.69% |
| Mar 31, 2024 | 55 | 8 | 17.02% |
| Dec 31, 2023 | 57 | 9 | 18.75% |
| Sep 30, 2023 | 50 | 8 | 19.05% |
| Jun 30, 2023 | 51 | 9 | 21.43% |
| Mar 31, 2023 | 47 | 5 | 11.90% |
| Dec 31, 2022 | 48 | - | - |
| Jun 30, 2022 | 42 | 16 | 61.54% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| Kyverna Therapeutics | 130 |
| Ocugen | 116 |
| Adlai Nortye | 109 |
| C4 Therapeutics | 104 |
| Assembly Biosciences | 73 |
| Prothena Corporation | 67 |
| Contineum Therapeutics | 51 |
RZLT News
- 1 hour ago - Rezolute price target raised to $14 from $10 at Maxim - TheFly
- 4 hours ago - Rezolute price target raised to $6 from $5 at Wedbush - TheFly
- 7 hours ago - Rezolute upgraded to Outperform from Market Perform at Citizens - TheFly
- 20 hours ago - Rezolute price target raised to $6 from $5 at BTIG - TheFly
- 21 hours ago - Rezolute price target raised to $14 from $10 at Maxim - TheFly
- 1 day ago - Rezolute provides interim update on ersodetug study - TheFly
- 1 day ago - Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism - GlobeNewsWire
- 20 days ago - Rezolute price target raised to $10 from $4 at Maxim - TheFly